Lemme GLP-1 Daily Review: What the Studies Actually Measured

Lemme GLP-1 Daily is probably the most searched natural GLP-1 capsule in the country, and the reviews are split almost down the middle. Some people swear by it. Others say it did nothing except cost them $80.

Both camps can be right. This is a well-built label with real studies behind each ingredient, sold on a promise the studies don't quite cover. Here's what's in the bottle, what the research actually measured, the lawsuits, the real price per day, and who we'd point elsewhere.

For the label checks that apply to every product in this aisle (proprietary blends, dose math, what a "GLP-1" claim can and can't mean), start with our buyer's guide to natural GLP-1 supplements. This review applies those same rules to one bottle.

What's in Lemme GLP-1 Daily

The product is now sold as Lemme Reset GLP-1 Production Support, which trips people up when they search. Same capsule, new name. A serving is 2 capsules with food, 30 servings a bottle, and the label is fully disclosed:

• Eriomin lemon fruit extract, 200 mg (standardized to 70% eriocitrin). This is the GLP-1 ingredient.
• Supresa saffron extract, 176.5 mg (standardized to 0.3% safranal). This is the appetite and snacking ingredient.
• Morosil red orange fruit extract, 400 mg (standardized to 0.8% anthocyanins). This is the body-composition ingredient.

No proprietary blend, no caffeine, no fiber load. Credit where it's due: most brands in this category hide their doses, and Lemme prints all three.

Lemme also states plainly that the product doesn't contain GLP-1, isn't synthetic GLP-1, and isn't a GLP-1 drug. That's the right thing to say. If you're weighing it against a prescription, our explainer on how natural GLP-1 support differs from GLP-1 agonists covers why those two things aren't on the same scale.

How it scores on our rubric

We score every product 1 to 5 on the same five axes, laid out on our scoring methodology page. Lemme lands at 18 out of 25.

• Pathway coverage, 3/5. GLP-1 signaling, fat and leptin signaling, and appetite through the saffron. Nothing for fullness or blood-sugar swings after a meal.
• Ingredients, 4/5. Three branded, standardized extracts at fully disclosed doses. That's the best part of this product.
• Science, 3/5. Each ingredient has human trials. The finished three-ingredient capsule has none published.
• Value, 4/5. Fair on subscription. The return fee takes some shine off the guarantee.
• Format and timing, 4/5. Two tasteless capsules once a day. Hard to get wrong.

The full card, with pros and cons side by side against the rest of the aisle, is on the Lemme GLP-1 Daily product page and in our GLP-1 support category.

The evidence, ingredient by ingredient

Eriomin: the GLP-1 numbers, and who they came from

This is where the "GLP-1" on the bottle comes from. In a 12-week randomized trial of 103 adults with prediabetes, Eriomin at 200, 400 or 800 mg a day lowered fasting blood glucose by about 5% and raised measured GLP-1 by about 15% versus baseline, with all three doses performing about the same (Ribeiro, Phytotherapy Research 2019). A 30-person crossover trial in people with raised blood sugar found a 17% GLP-1 rise at 200 mg (Cesar, Journal of Medicinal Food 2022), and a later 12-week trial reported a 22% rise alongside shifts in gut bacteria (Ramos, Food Science & Nutrition 2023).

So 200 mg, the dose in Lemme, is the studied dose. Good.

Two things to keep in view. First, the participants had elevated blood sugar, and the outcomes were metabolic markers. In the 2019 trial, the authors report that Eriomin didn't change body measurements or what people ate. Nobody in these trials was asked about cravings.

Second, don't over-read the percentages in either direction. Circulating GLP-1 is broken down within minutes, and commercial GLP-1 test kits disagree widely on absolute levels (Bak, Diabetes, Obesity and Metabolism 2014). A 15% rise on one assay is a real signal of activity. It isn't a number you can line up against another product's, or against a drug.

Supresa saffron: the snacking study

Lemme's "fewer snacking events" claims trace to saffron. The 176.5 mg dose matches an 8-week trial of 60 mildly overweight women, where a saffron stigma extract called Satiereal cut self-reported snacking frequency and produced more weight loss than placebo, with no dropouts blamed on the product (Gout, Nutrition Research 2010).

One caveat the marketing skips: Lemme uses Supresa, a different branded saffron extract. The milligrams match the trial exactly; whether the two extracts behave the same hasn't been tested head to head.

That's a genuinely relevant endpoint for a cravings product, and it's the strongest reason to buy this bottle. It's also one trial, in women only, with snacking logged by diary. If you take an antidepressant, read our note on saffron, 5-HTP and serotonin medications before adding it.

Morosil: the waistline ingredient

Morosil at 400 mg a day, the same dose Lemme uses, was tested for 12 weeks in overweight healthy volunteers. The extract group ended with lower body weight, BMI and waist and hip measurements than placebo (Cardile, Natural Product Research 2015). It's a small, older study, and it didn't measure appetite. Read it as supportive, not settled.

What's missing

No published trial tests these three extracts together in one capsule. That's normal for this category (it's true of almost every product we review, Ozzi included), but it's also exactly the gap the lawsuits went after.

The Lemme GLP-1 lawsuits

In February and March 2025, the same plaintiff filed proposed class actions against Lemme in California state court and in federal court in New York. The complaints argue that the brand implied weight-loss results the evidence doesn't support, that the ingredient studies don't cover the finished combination, and that natural GLP-1 lasts only a minute or two in the blood, compared with about a week for prescription agonists (as reported by NutraIngredients-USA, April 2025).

A Lemme spokesperson called the suits "frivolous." We couldn't find a ruling on the merits or a certified class. Treat the complaints as allegations, not findings.

Price per day

One-time, a bottle is $80 for 30 servings, which is $2.67 a day. The monthly subscription drops it to $64, or about $2.13 a day, and the multi-month subscriptions go a little lower.

The money-back guarantee covers a first single-bottle order in the US, minus a $9.99 processing fee. Multi-bottle packs and international orders aren't returnable, so if you want the guarantee, buy one bottle first.

Lemme also suggests 3 to 6 months of consistent use. Budget for that before you judge it on week two.

Who it's for, and who should skip it

Good fit: you want a caffeine-free capsule with a clean, disclosed label, your main problem is between-meal snacking, and you're willing to give it a few months.

Skip it if: you want to feel fuller at meals (there's no fiber doing that job), your cravings hit hardest after dinner and you want something built for that window, or you're on antidepressants and haven't cleared saffron with your doctor. If you're comparing it with other GLP-1 products, we've already run it head to head in Lemme vs Pendulum and Supergut vs Lemme.

The alternative we'd pick

If you want a capsule, our pick is the Ozzi Crave Crusher Capsules, which score 20 out of 25 on the same rubric. It covers five hunger pathways to Lemme's three: BIOMEnd butyrate for GLP-1 signaling, 500 mg of glucomannan for fullness, African mango and Metabolex chromium, all at disclosed doses and caffeine-free. It also comes in cheaper per day with a multi-bottle bundle (about $1.89 a serving).

Its cons are real. There's no published trial on the finished Ozzi formula either, the doses are moderate by design, and some people notice the natural butyrate smell. If you'd rather drink it, the Ozzi Crave Crusher drink adds allulose for a sweet evening drink. The full side-by-side is on our Ozzi vs Lemme comparison.

Disclosure: Ozzi sponsors Crave Crushers, and we may earn a commission on purchases made through links on this page. Rankings come from the published rubric on our methodology page, and Ozzi's downsides are listed on the same terms as every other product's.

Our verdict

Lemme GLP-1 Daily is one of the more honest-looking labels in the natural GLP-1 aisle: three branded extracts, each at a studied dose, nothing hidden. The saffron is the part with the most direct cravings evidence. The GLP-1 part is real but was measured in people with high blood sugar, on a marker that doesn't translate cleanly into appetite.

Buy it for steadier snacking habits over a few months. Don't buy it expecting a prescription-style effect, and buy one bottle first so the guarantee still applies.

References

• Ribeiro CB, Ramos FM, Manthey JA, Cesar TB. Effectiveness of Eriomin in managing hyperglycemia and reversal of prediabetes condition: a double-blind, randomized, controlled study. Phytotherapy Research, 2019. PubMed 31183921
• Cesar TB, Ramos FMM, Ribeiro CB. Nutraceutical eriocitrin (Eriomin) reduces hyperglycemia by increasing glucagon-like peptide 1 and downregulates systemic inflammation: a crossover-randomized clinical trial. Journal of Medicinal Food, 2022. PubMed 35796695
• Ramos FMM, Ribeiro CB, Cesar TB, et al. Lemon flavonoids nutraceutical (Eriomin) attenuates prediabetes intestinal dysbiosis: a double-blind randomized controlled trial. Food Science & Nutrition, 2023. PubMed 37970408
• Gout B, Bourges C, Paineau-Dubreuil S. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women. Nutrition Research, 2010. PubMed 20579522
• Cardile V, Graziano AC, Venditti A. Clinical evaluation of Moro (Citrus sinensis (L.) Osbeck) orange juice supplementation for the weight management. Natural Product Research, 2015. PubMed 25588369
• Bak MJ, Wewer Albrechtsen NJ, Pedersen J, et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes, Obesity and Metabolism, 2014. PubMed 25041349
• Lemme label, pricing and return terms: lemmelive.com product page, checked 2026-09-29.
• Lawsuit coverage: "Lemme facing class action over GLP-1 supplement claims," NutraIngredients-USA, April 30, 2025.